- Marx N, Walcher D. Vascular effects of PPARgamma activators - from bench to bedside. Prog Lipid Res. 2007;46:283-96 pubmed..This review will focus on the vascular effects of PPARgamma activators and summarize the current knowledge of their modulatory function on atherogenesis and vascular disease. ..
- Merkel M. [Diabetic dyslipoproteinemia: beyond LDL]. Dtsch Med Wochenschr. 2009;134:1067-73 pubmed publisher..Thus, statin therapy to decrease LDL cholesterol to target is the essential treatment for diabetic dyslipidemia to reduce cardiovascular risk. Other lipid lowering drugs can be added optionally...